The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab

Table 1

Comparison of patient demographics and characteristics of the AMD and AMD/ERM groups at baseline.

	AMD group	AMD/ERM group	𝑃 value
Number of patients	35	28	—
Mean age, years ± SD (range)*	66.3±9.9; (52–84)	68.6±9.4; (55–85)	0.38
Gender (female/male)^†	15/20	11/17	0.77
CNV type classic/nonclassic^†	12/23	11/17	0.68
Mean BCVA, logMAR ± SD (range)*	0.71±0.28; (0.3–1.3)	0.73±0.31; (0.3–1.3)	0.88
Mean CRT, 𝜇m ± SD (range)*	315±102; (275–462)	371±95; (298–519)	0.06
PED (%)^†	16 (45%)	9 (32%)	0.27

AMD, age-related macular degeneration; ERM, epiretinal membrane; BCVA, best corrected visual acuity; CRT, central retinal thickness; PED, pigment epithelium detachment; SD, standard deviation.
*Mann-Whitney 𝑈 test.
^†Chi-square test.